| AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis (NCT03718143) | NYU Langone Health | 2019-05-08 |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation (NCT03843528) | Johns Hopkins All Children's Hospital | 2019-05-01 |
| Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous Leukemia (NCT04158726) | Carevive Systems, Inc. | 2019-04-26 |
| Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia (NCT03760523) | H. Lee Moffitt Cancer Center and Research Institute | 2019-04-18 |
| Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia (NCT03672851) | Second Affiliated Hospital of Xi'an Jiaotong University | 2019-04-17 |
| Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients. (NCT03902769) | Rambam Health Care Campus | 2019-04-15 |
| Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement (NCT03724084) | National Cancer Institute (NCI) | 2019-04-10 |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT03802695) | Orca Biosystems, Inc. | 2019-04-08 |
| Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients (NCT04087967) | The First Affiliated Hospital of Soochow University | 2019-04-01 |
| Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (NCT03701308) | National Cancer Institute (NCI) | 2019-03-28 |
| A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission (NCT03850535) | Hoffmann-La Roche | 2019-03-25 |
| Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML) (NCT03410407) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2019-03-19 |
| A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT03797261) | AbbVie | 2019-03-18 |
| Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid Leukemia (NCT03806192) | University of Washington | 2019-03-16 |
| Early Palliative Care for Patients With Haematological Malignancies (NCT03800095) | University Hospital, Clermont-Ferrand | 2019-03-14 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (NCT03900949) | Uma Borate | 2019-03-13 |
| Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia (NCT05149339) | Zagazig University | 2019-03-01 |
| CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT (NCT03810196) | Children's Hospital of Philadelphia | 2019-03-01 |
| A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (NCT03839771) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2019-03-01 |
| Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia (NCT03705858) | Joseph Jurcic | 2019-02-28 |
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (NCT03839446) | Robert Redner, MD | 2019-02-28 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT03862157) | M.D. Anderson Cancer Center | 2019-02-27 |
| PTX3-targeted Antifungal Prophylaxis (NCT03828773) | Bochud Pierre-Yves | 2019-02-11 |
| Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid (NCT05297123) | First Affiliated Hospital Xi'an Jiaotong University | 2019-02-03 |
| Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial (NCT03735446) | Dana-Farber Cancer Institute | 2019-01-18 |
| Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy (NCT03450512) | Centre Hospitalier Universitaire, Amiens | 2019-01-14 |
| Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia (NCT03439371) | Centre Hospitalier Universitaire de Saint Etienne | 2019-01-08 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411) | Masonic Cancer Center, University of Minnesota | 2019-01-02 |
| Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML (NCT03719183) | Assiut University | 2019-01-01 |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (NCT03699475) | Bellicum Pharmaceuticals | 2018-12-27 |
| Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes (NCT03824080) | GWT-TUD GmbH | 2018-12-20 |
| A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (NCT03760666) | Clear Creek Bio, Inc. | 2018-12-20 |
| Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia (NCT03634228) | M.D. Anderson Cancer Center | 2018-12-17 |
| Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) (NCT03552029) | Daiichi Sankyo | 2018-12-12 |
| Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (NCT03737955) | University of Washington | 2018-11-30 |
| Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue (NCT03747757) | M.D. Anderson Cancer Center | 2018-11-29 |
| Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia (NCT03573024) | University of Colorado, Denver | 2018-11-28 |
| Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML) (NCT03790072) | TC Biopharm | 2018-11-27 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (NCT03555955) | Jazz Pharmaceuticals | 2018-11-20 |
| Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS (NCT03300492) | University Hospital, Basel, Switzerland | 2018-11-12 |
| Effect of Food on Blood Levels of ASTX727 (NCT03813186) | Astex Pharmaceuticals, Inc. | 2018-11-08 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation (NCT03734601) | Stanford University | 2018-11-05 |
| iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) (NCT03207334) | University of Florida | 2018-11-01 |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (NCT03661307) | M.D. Anderson Cancer Center | 2018-10-31 |
| Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia (NCT03455504) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2018-10-26 |
| Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT03586609) | M.D. Anderson Cancer Center | 2018-10-25 |
| Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML (NCT03709758) | Dana-Farber Cancer Institute | 2018-10-17 |
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia (NCT03616470) | GlycoMimetics Incorporated | 2018-10-15 |
| Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT (NCT03715621) | The First Affiliated Hospital of Soochow University | 2018-10-15 |
| Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy (NCT03603795) | French Innovative Leukemia Organisation | 2018-10-11 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers (NCT03589729) | M.D. Anderson Cancer Center | 2018-09-19 |
| Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm (NCT03531918) | Fred Hutchinson Cancer Center | 2018-09-14 |
| Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML (NCT03701217) | Nanfang Hospital, Southern Medical University | 2018-09-10 |
| The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML (NCT03665480) | Nanfang Hospital, Southern Medical University | 2018-09-04 |
| Psychological Intervention Mobile App for Patients With AML (NCT03372291) | Massachusetts General Hospital | 2018-09-01 |
| DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US (NCT02863458) | The Cleveland Clinic | 2018-09-01 |
| Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML (NCT03913312) | Ruijin Hospital | 2018-09-01 |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT (NCT03696537) | Naoyuki G. Saito, M.D., Ph.D. | 2018-08-29 |
| Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML) (NCT03609060) | French Innovative Leukemia Organisation | 2018-08-24 |
| Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT03671564) | Daiichi Sankyo Co., Ltd. | 2018-08-23 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies (NCT03465540) | Amgen | 2018-08-17 |
| Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood (NCT03793478) | Daiichi Sankyo | 2018-08-15 |
| Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy (NCT03435848) | BioSight Ltd. | 2018-08-14 |
| Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS (NCT03417154) | Masonic Cancer Center, University of Minnesota | 2018-08-13 |
| HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation (NCT03655145) | Assistance Publique - Hôpitaux de Paris | 2018-08-01 |
| Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML (NCT03642236) | Nanfang Hospital, Southern Medical University | 2018-08-01 |
| A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies (NCT03560882) | Joaquina Baranda | 2018-07-19 |
| Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients (NCT03594149) | Centre Henri Becquerel | 2018-07-18 |
| Guadecitabine Extension Study (NCT03603964) | Astex Pharmaceuticals, Inc. | 2018-07-18 |
| IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation (NCT03515512) | Massachusetts General Hospital | 2018-07-17 |
| Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) (NCT03568994) | Baylor College of Medicine | 2018-07-10 |
| Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia (NCT03515707) | Fred Hutchinson Cancer Center | 2018-07-10 |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03494569) | City of Hope Medical Center | 2018-07-06 |
| NGS in AML Relapse (NCT03582241) | University Hospital, Strasbourg, France | 2018-06-27 |
| Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT (NCT03530085) | Nanfang Hospital, Southern Medical University | 2018-06-15 |
| Immune Checkpoint Receptors in AML-Leukemic Initiating Cells (NCT03449745) | University Hospital, Bordeaux | 2018-05-29 |
| Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS (NCT03187288) | University Health Network, Toronto | 2018-05-25 |
| Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia (NCT03441048) | Medical College of Wisconsin | 2018-05-22 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758) | Brenda Cooper, MD | 2018-05-22 |
| A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML) (NCT04827069) | Sunshine Lake Pharma Co., Ltd. | 2018-05-18 |
| Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML (NCT03466294) | University of Colorado, Denver | 2018-05-15 |
| A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (NCT03530683) | Pfizer | 2018-05-14 |
| Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation (NCT03483324) | Angiocrine Bioscience | 2018-04-24 |
| Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 (NCT03338348) | University of Ulm | 2018-04-19 |
| Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (NCT03921047) | University of Southern California | 2018-04-12 |
| Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia (NCT03516760) | AvenCell Europe GmbH | 2018-04-11 |
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML (NCT03280030) | Novartis Pharmaceuticals | 2018-04-06 |
| Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03347994) | Justin Watts | 2018-04-01 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression (NCT03480360) | Dartmouth-Hitchcock Medical Center | 2018-03-28 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT03358719) | Roswell Park Cancer Institute | 2018-03-27 |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies (NCT03471260) | M.D. Anderson Cancer Center | 2018-03-19 |
| Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia (NCT03467386) | City of Hope Medical Center | 2018-03-19 |
| TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid (NCT03397173) | Case Comprehensive Cancer Center | 2018-03-16 |
| HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies (NCT03232268) | Institut Paoli-Calmettes | 2018-03-09 |
| Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients (NCT03488862) | UNC Lineberger Comprehensive Cancer Center | 2018-03-01 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT03795779) | iCell Gene Therapeutics | 2018-03-01 |